DOCSLIB.ORG

Listing of Global Companies with Ongoing Government Activity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Listing of Global Companies with Ongoing Government Activity COMPANY LINE OF BUSINESS TICKER V & P LABORATORY CO. LTD. PHARMACEUTICAL PREPARATIONS V & P SCIENTIFIC, INC PLASTICS PRODUCTS, NEC, NSK V B JEWELLERS PHARMACEUTICAL PREPARATIONS V C A LABORATORIOS S.R.L. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC V D SANE AYURVEDIC RESEARCH CENTRE MEDICINALS AND BOTANICALS, NSK V H B LIFE SCIENCES LIMITED PHARMACEUTICAL PREPARATIONS V H B LIFESCIENCE INCORPORATED PHARMACEUTICAL PREPARATIONS V I G BIOTEC PHARMACEUTICAL PREPARATIONS V I P PHARMACEUTICALS (INDIA) MEDICINALS AND BOTANICALS, NSK V J AYURVEDICS MEDICINALS AND BOTANICALS, NSK V K AYURVEDIC STORE MEDICINALS AND BOTANICALS, NSK V K HIMALYAN HERBAL MEDICINALS AND BOTANICALS, NSK V K S M HERBAL PRODUCTS MEDICINALS AND BOTANICALS, NSK V M COSTA SANTOS PHARMACEUTICAL PREPARATIONS V N POLYMERS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS V P PHARMA PHARMACEUTICAL PREPARATIONS V R HERBAL REMEDIES PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK V R HERBALS MEDICINALS AND BOTANICALS, NSK V R PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS V S BIDPHARMA RESEARCH & PROCESSING PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK V S D LIFE SCIENCES PHARMACEUTICAL PREPARATIONS V S INTERNATIONAL PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK V S P INTERNATIONAL PHARMACEUTICAL PREPARATIONS V V R ORGANICS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS V V S CHEMICALS PHARMACEUTICAL PREPARATIONS V V S PHARMACEUTICALS & CHEMICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS V&S PHARMACEUTICALS LIMITED MEDICINALS AND BOTANICALS, NSK V. K. AYURVEDIC AGENCIES MEDICINALS AND BOTANICALS, NSK V.P.H. OOO PHARMACEUTICAL PREPARATIONS V.P.PHARMACY REGISTERED ORDINARY PARTNERSHIP PHARMACEUTICAL PREPARATIONS V.R. LIFE SCIENCES PVT. LTD. PHARMACEUTICAL PREPARATIONS V.R. LIFE SCIENCES PVT. LTD. PHARMACEUTICAL PREPARATIONS V.S. PHARMA CO.,LTD. PHARMACEUTICAL PREPARATIONS V.S.M. GENEESMIDDELEN B.V. PHARMACEUTICAL PREPARATIONS V2SOFT INC. CUSTOM COMPUTER PROGRAMMING SERVICES, NSK VAADI HERBALS MEDICINALS AND BOTANICALS, NSK VAASANTHI HERBAL AND HEALTH PRODUCTS MEDICINALS AND BOTANICALS, NSK VAASAVAA PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VABRE S.A. MEDICINALS AND BOTANICALS, NSK VABRIELA S.R.L. PHARMACEUTICAL PREPARATIONS VACCINE CENTRE BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VACCINE TECHNOLOGIES INC BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VACCINES ON THE GO, INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VACOPHARM PHARMACEUTICAL JOINT STOCK COMPANY PHARMACEUTICAL PREPARATIONS VADA BIOTECH PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VADHU HERBAL BEAUTY PARLOUR MEDICINALS AND BOTANICALS, NSK VAIBHAV CHEMICALS PHARMACEUTICAL PREPARATIONS VAIBHAV DRUGS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAIDEHI PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAIDYA PATANKAR PHARMACY PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VAIDYA PATNAKAR DHARMACY PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAIDYNATH AYURVEDIC BHAWAN (PRIVATE) LIMITED MEDICINALS AND BOTANICALS, NSK VAIPANI HERBAL MEDICINALS AND BOTANICALS, NSK VAIPANI HERBAL AYURVEDIC PRTH PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VAISHALI AROMATICS PRIVATE LIMITED /VAISHALI INDIA PHARMACEUTICAL PREPARATIONS VAISHALI GROUP PHARMACEUTICAL PREPARATIONS VAISHALI PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS VAISHALI PHARMACHEM PHARMACEUTICAL PREPARATIONS VAISHNAVI DRUGS CHEMICALS PHARMACEUTICAL PREPARATIONS VAISHNAVI DRUGS&PHARMACEUTICAL DIST.. PHARMACEUTICAL PREPARATIONS VAISHNAVI PHARMA PHARMACEUTICAL PREPARATIONS VAISHNO DRUGS INTERMEDIATES PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAISHNVI AYURVEDIC AUSHDHALAY MEDICINALS AND BOTANICALS, NSK VAJRAA DHURKA HERBAL MEDICINALS AND BOTANICALS, NSK VAKSINDO SATWA NUSANTARA, PT BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VAL D' AFRIQUE PHARMACEUTICAL PREPARATIONS VALARMATHY AGENCIES PHARMACEUTICAL PREPARATIONS VALCO INSTRUMENTS COMPANY INC PROCESS CONTROL INSTRUMENTS VALCO LABORATORIES PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VALDHARA AYURVEDIC PHARMACY MEDICINALS AND BOTANICALS, NSK VALDHARA AYURVEDIC PHARMACY MEDICINALS AND BOTANICALS, NSK VALEANT CANADA HOLDINGS LIMITED PHARMACEUTICAL PREPARATIONS VALEANT CANADA LIMITEE PHARMACEUTICAL PREPARATIONS VALEANT FARMACEUTICA, S.A. MEDICINALS AND BOTANICALS, NSK VALEANT INTERNATIONAL (BARBADOS) SRL PHARMACEUTICAL PREPARATIONS VALEANT PHARMACEUTICALS INTERNATIONAL PHARMACEUTICAL PREPARATIONS VALEANT PHARMACEUTICALS INTERNATIONAL, INC PHARMACEUTICAL PREPARATIONS VRX VALEANT PHARMACEUTICALS NORTH AMERICA PHARMACEUTICAL PREPARATIONS VALEAS SPA INDUSTRIA CHIMICA E FARMACEUTICA PHARMACEUTICAL PREPARATIONS VALEDA HERBAL PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VALEDA PURE HERBAL COSEMETICS MEDICINALS AND BOTANICALS, NSK VALENTA FARM OAO MEDICINALS AND BOTANICALS, NSK VALENTIS UAB PHARMACEUTICAL PREPARATIONS VALIANT INDUSTRIES LIMITED PHARMACEUTICAL PREPARATIONS VALIDUS PHARMACEUTICALS LLC PHARMACEUTICAL PREPARATIONS VALLABH VIJAY & SONS PHARMACEUTICAL PREPARATIONS VALLALAR HERBAL HEALTH CENTER MEDICINALS AND BOTANICALS, NSK VALLE MEDIO S.R.L. PHARMACEUTICAL PREPARATIONS VALLEE S/A. PHARMACEUTICAL PREPARATIONS VALLEY HERBAL PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VALLEY VITAMINS II, INC. MEDICINALS AND BOTANICALS, NSK VALMED OOO PHARMACEUTICAL PREPARATIONS VALMO SCHNEIDER & CIA LTDA ME MEDICINALS AND BOTANICALS, NSK VALOSUN A.S. MEDICINALS AND BOTANICALS, NSK VALPHARMA INTERNATIONAL SPA PHARMACEUTICAL PREPARATIONS VALPHARMA S.A PHARMACEUTICAL PREPARATIONS VALUTRACK CORPORATION COMPUTER INTEGRATED SYSTEMS DESIGN, NSK VALVE & ACTUATION SERVICES, LLC INDUSTRIAL SUPPLIES, NSK VAMA WORLD OD HERBALS SHOBHA R MEDICINALS AND BOTANICALS, NSK VAMSHI EXPORT LIMITED MEDICINALS AND BOTANICALS, NSK VAMSI LABS LIMITED PHARMACEUTICAL PREPARATIONS VAN BEEK GLOBAL PHARMACEUTICAL PREPARATIONS VAN DETTE, EMILY SECRETARIAL AND COURT REPORTING, NSK VAN LIFE SCIENCES PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAN SANH ANIMAL FEED MANUFACTURING SERVICE AND TRADING CO LTD MEDICINALS AND BOTANICALS, NSK VANADEVI AYURVEDIC HEALTH PRODUCTS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VANADEVI AYURVEDIC HEALTH PRODUCTS PVT LTD MEDICINALS AND BOTANICALS, NSK VANANTARA HERBALS MEDICINALS AND BOTANICALS, NSK VANCE & HEALTH PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VANCE BIOENERGY SDN. BHD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VANDA PHARMACEUTICALS INC. PHARMACEUTICAL PREPARATIONS VNDA VANDIVER ENTERPRISES PLASTICS PRODUCTS, NEC, NSK VANELLI SRL MEDICINALS AND BOTANICALS, NSK VANESSA HERBALS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK VANGENT, INC. BUSINESS CONSULTING, NEC, NSK VANGENT, INC. BUSINESS CONSULTING, NEC, NSK VANGUARD NETWORK, THE PHARMACEUTICAL PREPARATIONS VANGUARD PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VANGUARD THERAPEUTICS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VANIKAR AYURVEDIC CHIKITSALAYA MEDICINALS AND BOTANICALS, NSK VANITHA AYURVEDICS MEDICINALS AND BOTANICALS, NSK VANQUISH PHARMACEUTI PHARMACEUTICAL PREPARATIONS VANSHREE AGRO TECH (HERBALS) MEDICINALS AND BOTANICALS, NSK VANSHREE AGRO TECH (HERBALS) MEDICINALS AND BOTANICALS, NSK VANSIL INDUSTRIA COMERCIO E REPRESENTACOES LTDA. PHARMACEUTICAL PREPARATIONS VANSREE AYURVEDICS MEDICINALS AND BOTANICALS, NSK VANTAGE HEALTHCARE PHARMACEUTICAL PREPARATIONS VANTAGE TECHNOLOGY INC. MEDICINALS AND BOTANICALS, NSK VANTECH INDUSTRIES LIMITED PHARMACEUTICAL PREPARATIONS VANTECH INDUSTRY LIMITED PHARMACEUTICAL PREPARATIONS VANTEN S.A. MEDICINALS AND BOTANICALS, NSK VANWAY PHARMACEUTICAL HOLDINGS LIMITED MEDICINALS AND BOTANICALS, NSK VANWORLD PHARMACEUTICAL (RUGAO) CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VANZED PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS VAPI CARE PHARMA PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VAPI CARE PHARMA PVT LTD PHARMACEUTICAL PREPARATIONS VAPI ORGANICS CHEMICALS PVT LTD PHARMACEUTICAL PREPARATIONS VARA S.A DE C.V. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VARDA BIOTECH (PRIVATE) LIMITED PHARMACEUTICAL PREPARATIONS VARDHAMAN LABORATORIES LIMITED PHARMACEUTICAL PREPARATIONS VARDHAMAN STONE SUPPLIERS MEDICINALS AND BOTANICALS, NSK VARDHMAN AYURVEDIC MEDICINALS AND BOTANICALS, NSK VARDHMAN ENGINEERING & MARKETING CORPORATION MEDICINALS AND BOTANICALS, NSK VARDHMAN EXPORTS PHARMACEUTICAL PREPARATIONS VARDHMAN LIFE SCIENCES PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VARDHMAN LIFE SCIENCES PVT LTD PHARMACEUTICAL PREPARATIONS VARDHMAN MEDICALS PHARMACEUTICAL PREPARATIONS VARDHMAN PHARMA MEDICINALS AND BOTANICALS, NSK VARGWARD LABOROTORIES PHARMACEUTICAL PREPARATIONS VARIATION BIOTECHNOLOGIES (US), INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VARICHEM CHEMICALS LTD PHARMACEUTICAL PREPARATIONS VARINDERA AYURVEDIC PROV.ST MEDICINALS AND BOTANICALS, NSK VARINDRA REFRIGERATION PHARMACEUTICAL PREPARATIONS VARIOUS VIEWS RESEARCH INC. COMMERCIAL NONPHYSICAL RESEARCH VARITEX PHARMA SP Z O O MEDICINALS AND BOTANICALS, NSK VARSHA MUTITECH PHARMACEUTICAL PREPARATIONS VARSHCHEM ENTERPRISES PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VARTAMA PHARMA OOO PHARMACEUTICAL PREPARATIONS VARUN FABRICATORS THANE W PHARMACEUTICAL PREPARATIONS VARUN FOOD PRODUCTS PHARMACEUTICAL PREPARATIONS VAS S.R.O. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC VASA PHARMACHEM PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VASAN AYURVEDIC SANSTHAN PROP. MEDICINALS AND BOTANICALS, NSK VASANT PHARMA PHARMACEUTICAL PREPARATIONS VASANTHA MEDICALS PHARMACEUTICAL PREPARATIONS VASAV PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS VASCULAR CONCEPTS LIMITED PHARMACEUTICAL PREPARATIONS VASHAW SCIENTIFIC, INC. PROFESSIONAL EQUIPMENT, NEC, NSK VASISHTA AYURVEDIC
Load more

Recommended publications
  • Otonomy Inc. 2021 Proxy Statement
    OTONOMY, INC. Dear Stockholder: I am pleased to invite you to attend the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Otonomy, Inc. (“Otonomy”), which will be held on June 22, 2021 at 8:00 a.m. Pacific Time. The Annual Meeting will be conducted virtually via live webcast. You will be able to attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/OTIC2021, where you will be able to listen to the meeting live, submit questions and vote online by entering the control number located on your proxy card. The attached Notice of Annual Meeting of Stockholders and proxy statement contain details of the business to be conducted at the Annual Meeting. Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the meeting. Therefore, I urge you to promptly vote and submit your proxy via the Internet, by phone, or by signing, dating and returning the enclosed proxy card in the enclosed envelope. If you decide to attend the Annual Meeting, you will be able to change your vote or revoke your proxy, even if you have previously submitted your proxy. On behalf of Otonomy, I would like to thank you for your continued support. Sincerely, David A. Weber, Ph.D. President and Chief Executive Officer OTONOMY, INC. 4796 Executive Drive San Diego, California 92121 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS Time and Date June 22, 2021 at 8:00 a.m. Pacific Time The Annual Meeting will be a completely virtual meeting of stockholders, to be conducted via live webcast.
    [Show full text]
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • Pharmaceuticals, Medical Devices and Biologics Regulatory and Policy Bulletin
    Antitrust Connection Spring 2009 To: Our Clients and Friends August 27, 2010 Pharmaceuticals, Medical Devices and Biologics Regulatory and Policy Bulletin Top News During China Visit, FDA Commissioner’s Focus Not on Heparin Investigation FDA Commissioner Margaret Hamburg’s recent trip to China focused primarily on avenues of collaboration and cooperation between the FDA and Chinese regulators rather than on the current investigation into the contamination of heparin, which has caused some to express concern that US legislators may perceive the two bodies as not trying to work effectively to determine the cause of the contamination. FDA officials have indicated that the issue was discussed, but it was not focused on during the meetings. Industry Expresses Concern Over New Drug User Fees The drug industry is expressing concern over the FDA’s recent increase in prescription drug user fee rates, saying that the increase of approximately 10 percent is not appropriate given the backlog and failure to meet other review deadlines. Industry has indicated that it would like more accountability and adherence to performance goals if will be paying such increased fees. As the FDA discusses drug user fees and other programs as part of the Prescription Drug User Fee Act legislative proposal, some consumer, safety, and patient groups are voicing their concern that the agency is not including them in its discussions of the Act. Official, Panel Members Criticize Glaxo’s Report on Avandia Committee Meeting An article in the New York Times indicates that a government official and some members of the FDA advisory panel that recently reviewed Avandia are critical of Glaxo’s letter to doctors participating in the TIDE trial, intended to compare the risks of Avandia with those of competing drug Actos.
    [Show full text]
  • Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016
    Immuno-Oncology Drug Development Workshop Hyatt Regency Washington on Capitol Hill Columbia A&B Ballroom Washington, DC October 13 - 14, 2016 Workshop Co-Chairs Maitreyee Hazarika, MD, Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr. Hazarika is a Senior Medical Officer in the Melanoma and Sarcoma Team in the Division of Oncology Products 2 (DOP2) of the Office of Hematology and Oncology Products (OHOP) in the Center for Drug Evaluation and Research (CDER) of the United States Food and Drug Administration (FDA). As a regulatory reviewer, she has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, which have included immunotherapies, targeted kinase inhibitors, immunomodulators and folate analog metabolic inhibitors. She has presented FDA review findings as a speaker at oncology drug advisory committee meetings and has authored manuscripts presenting summaries on FDA drug approvals. In addition to the regulatory experience at FDA, she has experience in global clinical drug development while an Associate Medical Director, Clinical Development at Celgene International and also provided consulting services as a subject matter expert in oncology and on regulatory and clinical aspects of pharmaceutical drug development while a Principal Consultant at Parexel Consulting. Dr. Hazarika received her MBBS and MD degrees in India and completed her internship and residency in Internal Medicine and fellowship in Medical Oncology and Hematology at the New York University School of Medicine. As a fellow, she co-authored a book chapter while active in clinical research in ovarian cancer. Marc Theoret, MD, Lead Medical Officer, Division of Oncology Products 2, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, FDA Dr.
    [Show full text]
  • Ste28.Pdf(469KB)
    Shiri Breznitz PhD Candidate, Dept. of Geography, University of Cambridge Email - [email protected] Research: My main focus is regional economic development. I am particularly interested in university-industry relationships and their influence on local economies. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz 28 Science, Technology and the Economy Program (STE) Working Papers Series STE-WP - 28 - 2005 From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Shiri Breznitz Department of Geography University of Cambridge STE – WP 28 May 2005 This is a report on a research project conducted as part of the activities of the Science Technology and the Economy Program, (STE), at the Samuel Neaman Institute for Advanced Studies in Science and Technology. This research was carried out as part of a larger project on the Role of the University in Regional Economic Development. The author is grateful to the MIT Industrial Performance Center (IPC), the Cambridge Political Economy Society Trust, and the STE program at the Samuel Neaman Institute, for their generous support of this research. This paper presents the author’s own view and not that of the Samuel Neaman Institute for Advanced Studies in Science and Technology or any members of its staff. From Ivory Tower to Industrial Promotion: The Case of Yale University and the Biotechnology Cluster in New Haven, Connecticut Abstract In 2001 Ernst & Young ranked the state of Connecticut seventh in the nation with respect to the number of biotech firms operating within its borders relative to its population (Ernst & Young, 2001).
    [Show full text]
  • Fiscal Year 2006/2007 Office of Research University of South Florida
    REPORT OF RESEARCH ACTIVITIES Fiscal Year 2006/2007 Office of Research University of South Florida December 2007 Office of Research University of South Florida 30338 USF Holly Drive Tampa, Florida 33620-3033 Phone: 813-974-5570 Fax: 813-974-3348 Email: [email protected] This document is also available on the USF Office of Research Web site at www.research.usf.edu FY06/07 TABLE OF CONTENTS SECTION 1 . 1-6 z Contact Information { Office of Research { Research Technologies { Research Resources { Sponsored Research { Research Integrity and Compliance { Comparative Medicine { Technology Development { Patents & Licensing { USF Research Foundation z Office of Research Web Site http://www.research.usf.edu z Research Activity Reports http://reports.research.usf.edu SECTION 2 . 7- 50 z Awards Data SECTION 3 . 51-186 z Project Awards: Detailed Funding SECTION 4 . 187-202 z Non-Project Awards: Detailed Funding SECTION 5 . 203-218 z Internal Awards Programs { Program Overview { Research Council Members { 2006 - 2007 Awards Table { Five-Year Summary { Detailed Funding SECTION 6 . 219-225 z Proposal Data UNIVERSITY OF SOUTH FLORIDA OFFICE OF RESEARCH REPORT OF RESEARCH ACTIVITIES FISCAL YEAR 2006/2007 SECTION 1 CONTACTS 1 2 Organizational and Contact Information as June 30, 2007 Office of Research Chang, Ph.D., Robert [email protected] (813) 974-5481 Vice President for Research Pope, Priscilla [email protected] (813) 974-2897 Associate Vice President Casto, Ph.D., Rod [email protected] (813) 974-1082 Associate Vice President
    [Show full text]
  • 204200Orig1s000 204200Orig2s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204200Orig1s000 204200Orig2s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 204-200 and 204-640 Priority or Standard Standard Submit Date(s) March 7, 2012 Received Date(s) March 7, 2012 PDUFA Goal Date January 7, 2013 Division / Office DPARP/OND Reviewer Name(s) Peter Starke, MD Review Completion Date October 29, 2012 Established Name Epinephrine injection, USP, 1mg/mL (Proposed) Trade Name Adrenalin® Therapeutic Class Catecholamine Applicant JHP Pharmaceuticals, LLC Formulation(s) Solution for injection Proposed Dosing Hypersensitivity reactions: IM or SC Regimen injection(b) (4) [Ophthalmic use: Topical irrigation or intraocular bolus injection] Proposed Indication(s) Hypersensitivity reactions: severe acute anaphylactic reactions, (b) (4) [Ophthalmic use: induction and maintenance of mydriasis during cataract surgery] Intended Population(s) Hypersensitivity reactions: No age restrictions [Ophthalmic use: No age restrictions] Reference ID: 3209828 Clinical Review ● Peter Starke, MD NDA 204-200 ● Adrenalin® (epinephrine) MEDICAL OFFICER REVIEW Division of Pulmonary, Allergy and Rheumatology Products (DPARP) SUBMISSIONS REVIEWED IN THIS DOCUMENT Document Date CDER Stamp Date Submission Comments March 7, 2012 March 7, 2012 SD-1, eCTD-0000 New NDA submission April 9, 2012 April 9, 2012 SD-2, eCTD-0001 PREA waiver request – Anaphylaxis April 9, 2012 April 9, 2012 SD-3, eCTD-0002 PREA waiver request – Mydriasis April 18, 2012 April 18, 2012 SD-4, eCTD-0003 Request for proprietary name review Sept 5, 2012 Sept 6, 2012 SD-22, eCTD-0021 Draft Ophthalmic Labeling Oct 22, 2012 Oct 22, 2012 SD-27, eCDT-0026 Certification that EpiPen is the reference for the 505(b)(2) application RECOMMENDED REGULATORY ACTION NDA/SUPPLEMENTS: X APPROVAL COMPLETE RESPONSE OTHER ACTION: 2 Reference ID: 3209828 Clinical Review ● Peter Starke, MD NDA 204-200 ● Adrenalin® (epinephrine) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ........................................
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 Phathom Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 100 Campus Drive, Suite 102 Florham Park, NJ 07932 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS AND PROXY STATEMENT Dear Stockholder: The annual meeting of stockholders of Phathom Pharmaceuticals, Inc.
    [Show full text]
  • Margin Stocks, Notice 97-22
    F e d e r a l R e s e r v e B a n k OF DALLAS ROBERT D. MCTEER, JR. _____ p r e s i d e n t DALLAS, TEXAS AND CHIEF EXECUTIVE OFFICER 75265-5906 March 10, 1997 Notice 97-22 TO: The Chief Executive Officer of each member bank and others concerned in the Eleventh Federal Reserve District SUBJECT Over-the-Counter (OTC) Margin Stocks DETAILS The Board of Governors of the Federal Reserve System has revised the list of over- the-counter (OTC) stocks that are subject to its margin regulations, effective February 10, 1997. Included with the list is a listing of foreign margin stocks that are subject to Regulation T. The foreign margin stocks listed are foreign equity securities eligible for margin treatment at broker- dealers. The Board publishes complete lists four times a year, and the Federal Register announces additions to and deletions from the lists. ATTACHMENTS Attached are the complete lists of OTC stocks and foreign margin stocks as of February 10, 1997. Please retain these lists, which supersede the complete lists published as of February 12, 1996. Announcements containing additions to and deletions from the lists will be provided quarterly. MORE INFORMATION For more information regarding marginable OTC stock requirements, please contact Eugene Coy at (214) 922-6201. For additional copies of this Bank's notice and the complete lists, please contact the Public Affairs Department at (214) 922-5254. Sincerely yours, yf f a * / ' . For additional copies, bankers and others are encouraged to use one of the following toll-free numbers in contacting the Federal Reserve Bank of Dallas: Dallas Office (800) 333 -4460; El Paso Branch Intrastate (800) 592-1631, Interstate (800) 351-1012; Houston Branch Intrastate (800) 392-4162, Interstate (800) 221-0363; San Antonio Branch Intrastate (800) 292-5810.
    [Show full text]
  • Case 3:17-Cv-05244 Document 1 Filed 04/03/17 Page 1 of 100
    Case 3:17-cv-05244 Document 1 Filed 04/03/17 Page 1 of 100 1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT, WESTERN DISTRICT OF WASHINGTON AT SEATTLE 8 9 AMBER RAINEY, CHRISTINA KOLLMEYER, and LISA VOGEL, 10 No. Plaintiffs, 11 COMPLAINT v. 12 MYLAN SPECIALTY, L.P., a Delaware 13 limited partnership, 14 Defendant. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 COMPLAINT Case No. 1918 EIGHTH AVENUE, SUITE 3300 • SEATTLE, WA 98101 (206) 623-7292 • FAX (206) 623-0594 010648.11 949197 V1 Case 3:17-cv-05244 Document 1 Filed 04/03/17 Page 2 of 100 1 TABLE OF CONTENTS 2 Page 3 I. INTRODUCTION ...............................................................................................................1 4 II. PARTIES .............................................................................................................................7 5 A. Plaintiffs ...................................................................................................................7 6 B. Defendant .................................................................................................................8 7 III. JURISDICTION AND VENUE ..........................................................................................8 8 IV. DRUG PRICING IN THE UNITED STATES ....................................................................9 9 A. The Entities Involved in Drug Pricing .....................................................................9 10 B. Different Prices for Different Players ....................................................................10
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]